ArticleBMC cancer2017

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

Johan Falkenius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.